Encouraging results: Novo Nordisks Wegovy, for example, has shown a 20% reduction in heart attack, stroke, or death from heart disease in recent trials
Participants were randomly assigned in a 1:1 ratio to receive either semaglutide 50 mg or a placebo once daily for 68 weeks
For more information or to learn how to participate in clinical trials, call 305-842-2000 or visit www.omnicureresearch.com Novo Nordisk #Ozempic #KidneyHealth #DiabetesType2 #ClinicalResearch #OmnicureResearch #FLOWStudy #InnovationInHealth #ProtectYourKidneys To view or add a comment, sign in Today, more than 1 billion people live with obesity, a condition closely linked to cardiometabolic diseases such as type 2 diabetes and cardiovascular disease
Paul did, even pleasantly surp
Consult your doctor Limited data is available regarding the usage of Glutadee-1200 Injection 1's in children, so please consult a doctor
Gastrointestinal Disorders : Semaglutide's effects on gastric emptying and gut motility have sparked interest in its application for gastrointestinal disorders